Prevalence and Risk Factors of Atherosclerosis in Patients with Psoriatic Arthritis
Section snippets
Patients
Patients 18 years of age or older who were diagnosed as having PsA and were being routinely treated at our medical center’s Department of Rheumatology were consecutively invited to participate in this study. All patients who agreed to be part of the study were unselectively recruited and evaluated. They all fulfilled the currently accepted criteria for psoriasis, defined as the presence of typical skin lesions confirmed by a dermatologist, and for PsA, ie, the presence of a rheumatoid
Results
Table 1 summarizes the demographic and anthropomorphic data of the entire study cohort. The gender distribution for the 2 groups was similar, but the PsA group was significantly older and had a higher mean body weight and BMI. Most of the patients had psoriasis and PsA for years and most had a polyarticular pattern of arthritis (Table 2). The laboratory findings are summarized in Table 3.
Discussion
Chronic inflammatory conditions are increasingly linked to accelerated atherosclerosis (1, 2, 3, 4, 5), but their association with PsA has not been investigated. Our findings in the present study demonstrated greater thickness of the common carotid artery in PsA patients than in healthy controls. This increased IMT correlated with several tested parameters, such as the duration of skin and joint disease, spine involvement and levels of fibrinogen, as well as with conventional risk factors of
Acknowledgment
Esther Eshkol is thanked for editorial assistance.
References (34)
- et al.
Psoriatic arthritis
Semin Arthritis Rheum
(1973) - et al.
Disease concomitance in psoriasis
J Am Acad Dermatol
(1995) - et al.
Dyslipidaemia in the course of active rheumatoid arthritis
Semin Arthritis Rheum
(1992) - et al.
Hyperlipoproteinaemia and psoriasis
Lancet
(1976) - et al.
Lipid profile, insulin secretion, and insulin sensitivity in psoriasis
J Am Acad Dermatol
(2003) - et al.
Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis?
J Am Acad Dermatol
(1994) - et al.
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Lancet
(2002) - et al.
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy
Am J Med
(2004) - et al.
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors
Arthritis Rheum
(2001) - et al.
Cardiovascular mortality in women with rheumatoid arthritis
J Rheumatol
(1995)
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients
Arthritis Rheum
Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95
J Rheumatol
Premature coronary-artery atherosclerosis in systemic lupus erythematosus
N Engl J Med
Psoriatic arthritis
Exp Opin Investig Drugs
Mortality studies in psoriatic arthritis: results from a single outpatient clinicI. Causes and risk of death
Arthritis Rheum
Mortality studies in psoriatic arthritis: results from a single outpatient centerII. Prognostic indicators for death
Arthritis Rheum
Increased risk for cardiovascular mortality in psoriatic inpatients but not outpatients
Eur J Epidemiol
Cited by (192)
Cardiovascular Diseases in the Patients With Psoriatic Arthritis
2023, Current Problems in CardiologyCitation Excerpt :Recent studies have reported that the presence of hyperuricemia in patients with PsA due to increased cell turnover and release of inflammatory mediators may lead to an inflammatory joint condition.3,20 In addition, there is an increased frequency of sub-clinical atherosclerosis characterized by endothelial dysfunction and increased carotid artery intima-media thickness in PsA patients without clinically diagnosed CVD or associated risk factors.21,22 The final common pathway for rheumatologic diseases and CVD is inflammation, the degree of which correlates to morbidity, and mortality.23
Comorbidities in Psoriatic Arthritis: A Narrative Review
2023, Clinical TherapeuticsEvidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis
2023, Rheumatic Disease Clinics of North AmericaAmplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease
2019, Autoimmunity ReviewsCHARACTERISTICS OF CARDIOVASCULAR RISK IN PATIENTS WITH PSORIATIC ARTHRITIS
2024, Vestnik Sovremennoi Klinicheskoi Mediciny